Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals PLC

  • Price (USD)4.99
  • Today's Change0.03 / 0.60%
  • Shares traded350.56k
  • 1 Year change47.63%
  • Beta1.6630
Data delayed at least 15 minutes, as of Nov 15 2019 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Avadel Pharmaceuticals, PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company offers its products in various categories, including hospital, including Bloxiverz, Vazculep and Akovaz, and pediatrics, including Karbinal ER, Cefaclor for Oral Suspension, AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Cefaclor is indicated for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections, caused by susceptible organisms.

  • Revenue in USD (TTM)74.74m
  • Net income in USD-101.53m
  • Incorporated2017
  • Employees144.00
  • Location
    Avadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
  • Phone+353 14851200
  • Fax+353 15261077
  • Websitehttps://www.avadel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
22nd Century Group Inc25.71m-29.28m179.85m82.00--3.25--7.00-0.2345-0.23450.2060.43980.34678.8930.06313,485.10-39.49-30.76-42.86-33.651.18-1.23-113.90-91.999.02-6.190.0207--59.1929.4238.85---2.56--
Palatin Technologies, Inc.60.30m35.77m181.30m18.006.131.785.063.010.1290.1290.27770.44330.839--2.003,350,027.0049.77-11.6755.55-21.78----59.32-12.28----0.0033---10.18--47.81--42.09--
Galectin Therapeutics Inc0.00-18.55m183.74m6.00--3.70-----0.4189-0.41890.000.91220.00----0.00-34.80-101.73-36.36-118.42-----------89.850.00------13.85------
Fulcrum Therapeutics Inc0.00-78.83m186.72m62.00---------3.54-3.540.002.40------0.00--------------------0.0009-------54.30------
Avadel Pharmaceuticals PLC (ADR)74.74m-101.53m186.88m144.00------2.50-2.74-2.732.01-0.47590.32433.445.95519,006.90-44.05-11.50-54.04-16.2680.8789.94-135.85-19.492.82-4.311.15---40.3989.92-247.59--81.34--
Hookipa Pharma Inc-100.00bn-100.00bn187.26m60.00--1.38----------5.35----------------------------0.0377-------27.62------
Syndax Pharmaceuticals Inc1.52m-60.88m187.54m38.00--4.26--123.71-2.11-2.110.05181.620.0175--6.4539,894.74-70.45-55.88-88.53-64.01-----4,016.10-4,078.62----0.00---28.04---21.64--37.53--
Calithera Biosciences Inc0.00-87.63m187.68m79.00--1.56-----2.08-
Exicure Inc992.00k-21.08m187.71m33.00--2.89--189.22-0.4339-0.43390.02010.85470.0182--33.6336,740.74-38.56---45.94-------2,124.70-----27.980.0703---98.79---86.17------
Nature's Sunshine Prod.367.89m2.85m187.71m905.0068.351.4814.530.51020.14210.142118.856.561.812.1747.18406,512.701.431.722.052.4774.0173.860.78750.98161.016.220.0117248.076.66-0.272893.34---10.82--
Chromadex Corp38.34m-32.92m189.46m100.00--11.63--4.94-0.5955-0.59550.69340.27350.79282.058.17383,360.00-68.07-44.49-106.97-62.6953.8145.40-85.86-55.081.11-61.460.4074--48.8425.44-101.55--45.02--
NuCana PLC (ADR)0.00-20.58m193.04m24.00--2.05-----0.6385-0.63850.002.920.00----0.00-18.68---19.93----------------------40.05------
Spero Therapeutics Inc16.21m-46.54m195.49m41.00--2.06--12.06-2.59-2.590.90934.970.1304--3.72395,341.50-37.44---41.82-------287.11------0.00--100.40--9.62------
Evelo Biosciences Inc0.00-78.32m196.04m75.00--2.43-----2.44-2.440.002.510.00----0.00-54.62---58.52--------------0.1953-------78.38------
Kaleido Biosciences Inc0.00-88.05m197.21m118.00--2.99-----3.85-3.850.002.200.00----0.00-92.00---101.66--------------0.1847-------124.04------
Kalvista Pharmaceuticals Inc15.78m-23.12m197.22m45.00--1.94--12.50-1.36-1.360.94175.720.1778--1.73350,600.00-26.05---32.89-------146.57------0.00--92.13---31.71------
Data as of Nov 15 2019. Currency figures normalised to Avadel Pharmaceuticals PLC's reporting currency: US Dollar USD

Institutional shareholders

50.97%Per cent of shares held by top holders
HolderShares% Held
Brandes Investment Partners LPas of 30 Sep 20196.18m16.55%
Broadfin Capital LLCas of 04 Oct 20193.10m8.31%
Deerfield Management Company LPas of 30 Sep 20192.72m7.29%
Brandes Investment Partners (Europe) Ltd.as of 31 Dec 20181.72m4.60%
Brown Capital Management LLCas of 30 Sep 20191.70m4.54%
Renaissance Technologies LLCas of 30 Sep 2019822.01k2.20%
Tekla Capital Management LLCas of 30 Sep 2019814.59k2.18%
Columbia Management Investment Advisers LLCas of 30 Sep 2019764.57k2.05%
Morgan Stanley & Co. LLCas of 30 Sep 2019629.49k1.69%
DWS Investment Management Americas, Inc.as of 30 Sep 2019588.31k1.58%
More ▼
Data from 31 Dec 2018 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.